Comparison of plasma from healthy nonsmokers, smokers, and lung cancer patients: Pattern-based differentiation profiling of low molecular weight proteins and peptides by magnetic bead technology with MALDI-TOF MS

Dr. Panjwani Center for Molecular Medicine and Drug Research, University of Karachi, Karachi, Pakistan.
Biomarkers (Impact Factor: 2.26). 02/2012; 17(3):223-30. DOI: 10.3109/1354750X.2012.657245
Source: PubMed


Smoking is the major contributor of lung cancer (LC), which accounts for millions of death.
This study focused on the correlation between the proteomic profiling of LC patients, and healthy nonsmokers and smokers.
Pattern-based peptide profiling of 186 plasma samples was performed through reversed-phase chromatography-18 magnetic bead fractionation coupled with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis and resulted data were evaluated statistically by ClinProTool.
Marker peaks at m/z 1760, 5773, 5851, 2940, and 7172 were found with an excellent statistical figure.
Selected marker peaks can be served as a differentiated tool of LC patients with high sensitivity and specificity.

62 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Smoking is the leading cause of death in the world. This study focused on the difference of the serum proteomic profiling between healthy smokers and nonsmokers in order to find smoking-specific serum biomarkers. Pattern-based proteomic profiling of 100 serum samples (from 50 Chinese male smokers and 50 matched nonsmokers) was performed through magnetic bead fractionation coupled with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis (MALDI-TOF-MS) and resulting data were statistically analyzed by Ciphergen ProteinChip software 3.0.2. We found 72 serum peaks were significantly different between smokers and nonsmokers (P < 0.05). Marker peaks of mass-to-charge ratio (m/z) 3159.13, 7561.03 and 9407.32 were smoking-specific. The preliminary data suggested that smoking-specific serum biomarkers could be detected in humans.
    Chinese medical journal 09/2012; 125(17):3027-32. DOI:10.3760/cma.j.issn.0366-6999.2012.17.011 · 1.05 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Renal biopsy is necessary for diagnosing the pathological changes of primary nephrotic syndrome (NS). However, it is invasive, time-consuming and can not be performed frequent on the same patient. Thus, development of a non-invasive and rapid diagnostic method may improve clinical patient management. Proteomic tool magnetic bead-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MB-based MALDI TOF MS) was applied to serum to determine peptidome patterns that are characteristic of different pathological changes. Serum specimen from 114 patients with NS (62 were minimal change disease (MCD), 30 were membranous nephropathy (MN), and 22 were focal segmental glomerulosclerosis (FSGS)) and 60 normal individuals were analyzed using MB-based MALDI TOF MS. The peptidome pattern was generated by genetic algorithms using a training set of 31 MCD, 15 MN, 11 FSGS and 30 normal individuals and was validated by an independent testing set of the remaining samples. The serum peptidome pattern, based on a panel of 14 peaks, accurately recognized samples from MCD, MN, FSGS and healthy control with sensitivities of 93.5%, 86.7%, 63.6% and 90.0%, and specificities of 98.2%, 94.4%, 100% and 89.5%, respectively. Moreover, one peptide from peptidome pattern was identified by liquid chromatography tandem mass spectrometry (LC MS/MS) as fibrinogen A. Detection of the serum peptidome pattern is a rapid, non-invasive, high-throughout, and reproducible method for identifying the pathological patterns of patients with nephrotic syndrome.
    Chinese medical journal 12/2012; 125(24):4418-23. DOI:10.3760/cma.j.issn.0366-6999.2012.24.017 · 1.05 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent developments in mass spectrometry have introduced clinical proteomics to the forefront of diseases diagnosis, offering reliable, robust and efficient analytical method for biomarker discovery and monitoring. MALDI-TOF is a powerful tool for surveying proteins and peptides comprising the realm for clinical analysis. MALDI-TOF has the potential to revolutionize cancer diagnostics by facilitating biomarker discovery, enabling tissue imaging and quantifying biomarker levels. Healthy (control) and cancerous tissues can be analyzed on the basis of mass spectrometry (MALDI-TOF) imaging to identify cancer-specific changes that may prove to be clinically useful. We review MALDI-TOF profiling techniques as tools for detection of cancer biomarkers in various cancers. We mainly discuss recent advances including period from 2011 to 2013.
    Journal of pharmaceutical and biomedical analysis 03/2014; 95C:245-255. DOI:10.1016/j.jpba.2014.03.007 · 2.98 Impact Factor
Show more

Similar Publications